1iyk
From Proteopedia
(Difference between revisions)
| (8 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | {{STRUCTURE_1iyk| PDB=1iyk | SCENE= }} | ||
| - | ===Crystal structure of candida albicans N-myristoyltransferase with myristoyl-COA and peptidic inhibitor=== | ||
| - | {{ABSTRACT_PUBMED_12401496}} | ||
| - | == | + | ==Crystal structure of candida albicans N-myristoyltransferase with myristoyl-COA and peptidic inhibitor== |
| - | [[http://www.uniprot.org/uniprot/NMT_CANAL NMT_CANAL | + | <StructureSection load='1iyk' size='340' side='right'caption='[[1iyk]], [[Resolution|resolution]] 2.30Å' scene=''> |
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[1iyk]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Candida_albicans Candida albicans]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1IYK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1IYK FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=MIM:[CYCLOHEXYLETHYL]-[[[[4-[2-METHYL-1-IMIDAZOLYL-BUTYL]PHENYL]ACETYL]-SERYL]-LYSINYL]-AMINE'>MIM</scene>, <scene name='pdbligand=MYA:TETRADECANOYL-COA'>MYA</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1iyk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1iyk OCA], [https://pdbe.org/1iyk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1iyk RCSB], [https://www.ebi.ac.uk/pdbsum/1iyk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1iyk ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Function == | ||
| + | [https://www.uniprot.org/uniprot/NMT_CANAL NMT_CANAL] Adds a myristoyl group to the N-terminal glycine residue of certain cellular proteins. Substrate specificity requires an N-terminal glycine in the nascent polypeptide substrates. Ser is present at position 5 in almost all known N-myristoyl proteins and Lys is commonly encountered at postion 6. Basic residues are preferred at positions 7 and 8.<ref>PMID:1569105</ref> <ref>PMID:8300631</ref> <ref>PMID:9115247</ref> | ||
| + | == Evolutionary Conservation == | ||
| + | [[Image:Consurf_key_small.gif|200px|right]] | ||
| + | Check<jmol> | ||
| + | <jmolCheckbox> | ||
| + | <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/iy/1iyk_consurf.spt"</scriptWhenChecked> | ||
| + | <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | ||
| + | <text>to colour the structure by Evolutionary Conservation</text> | ||
| + | </jmolCheckbox> | ||
| + | </jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1iyk ConSurf]. | ||
| + | <div style="clear:both"></div> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Myristoyl-CoA:protein N-myristoyltransferase (Nmt) is a monomeric enzyme that catalyzes the transfer of the fatty acid myristate from myristoyl-CoA to the N-terminal glycine residue of a variety of eukaryotic and viral proteins. Genetic and biochemical studies have established that Nmt is an attractive target for antifungal drugs. We present here crystal structures of C. albicans Nmt complexed with two classes of inhibitor competitive for peptide substrates. One is a peptidic inhibitor designed from the peptide substrate; the other is a nonpeptidic inhibitor having a benzofuran core. Both inhibitors are bound into the same binding groove, generated by some structural rearrangements of the enzyme, with the peptidic inhibitor showing a substrate-like binding mode and the nonpeptidic inhibitor binding differently. Further, site-directed mutagenesis for C. albicans Nmt has been utilized in order to define explicitly which amino acids are critical for inhibitor binding. The results suggest that the enzyme has some degree of flexibility for substrate binding and provide valuable information for inhibitor design. | ||
| - | + | Crystal structures of Candida albicans N-myristoyltransferase with two distinct inhibitors.,Sogabe S, Masubuchi M, Sakata K, Fukami TA, Morikami K, Shiratori Y, Ebiike H, Kawasaki K, Aoki Y, Shimma N, D'Arcy A, Winkler FK, Banner DW, Ohtsuka T Chem Biol. 2002 Oct;9(10):1119-28. PMID:12401496<ref>PMID:12401496</ref> | |
| - | + | ||
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | < | + | </div> |
| + | <div class="pdbe-citations 1iyk" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Candida albicans]] | [[Category: Candida albicans]] | ||
| - | [[Category: | + | [[Category: Large Structures]] |
| - | [[Category: Aoki | + | [[Category: Aoki Y]] |
| - | [[Category: | + | [[Category: Banner DW]] |
| - | [[Category: | + | [[Category: D'Arcy A]] |
| - | [[Category: Fukami | + | [[Category: Fukami TA]] |
| - | [[Category: Morikami | + | [[Category: Morikami K]] |
| - | [[Category: Ohtsuka | + | [[Category: Ohtsuka T]] |
| - | [[Category: Shiratori | + | [[Category: Shiratori Y]] |
| - | [[Category: Sogabe | + | [[Category: Sogabe S]] |
| - | [[Category: Winkler | + | [[Category: Winkler FK]] |
| - | + | ||
Current revision
Crystal structure of candida albicans N-myristoyltransferase with myristoyl-COA and peptidic inhibitor
| |||||||||||
Categories: Candida albicans | Large Structures | Aoki Y | Banner DW | D'Arcy A | Fukami TA | Morikami K | Ohtsuka T | Shiratori Y | Sogabe S | Winkler FK

